UK court clears the way for controversial puberty blocker trial involving 226 children

On 31 July 2026, the UK High Court dismissed a legal challenge that sought to block a new clinical trial involving puberty blockers. The trial, in which up to 226 children with gender dysphoria—girls aged 11 and boys aged 12 and over—will be randomly assigned either to immediate treatment or to a group that must wait twelve months, may go ahead. The judge ruled that approving such a study is a matter for health regulators, not the courts.

What the legal challenge was about

The case was brought by the British parents' group Bayswater Support Group, detransitioner Keira Bell and lawyer James Esses. They argued that the trial fails to meet the legal and ethical thresholds that apply to research involving vulnerable children. They pointed out that the long-term effects of puberty blockers on bone development, fertility and psychological wellbeing have not been sufficiently studied to justify exposing children to them at random—even within a controlled research setting. The trial is being launched after the UK's National Health Service stopped providing the blockers outside research settings in 2024, following the conclusion of the Cass Review that the evidence for their effectiveness was "strikingly weak". The UK is not alone in this: an overview of the international reassessment shows that Sweden, Finland and Denmark have also restricted puberty blockers to research settings. The UK's medicines regulator, the MHRA, had previously expressed concerns about "potentially significant biological harm". A more detailed account of the trial and the parties who brought the legal challenge can be found at genderzorgen.nl.

Criticism of the Dutch Protocol too

The ruling does not stand alone. Journalist Bernard Lane, who follows international developments in gender healthcare on his platform Gender Clinic News, also points in his report on the case to growing criticism from the Netherlands of the so-called Dutch Protocol—the treatment approach underpinning many puberty blocker programmes worldwide. Doctors including Armand Girbes and Dorine Sellenraad argue that the protocol's "cautious" reputation does not match reality: the diagnosis remains poorly defined, comorbidities such as autism and trauma are not sufficiently taken into account, and around 82 per cent of adolescents who start blockers ultimately go on to receive cross-sex hormones—despite the protocol having been intended precisely as a way to create time and space for uncertainty.

Why this is more than a local issue

For parents and clinicians outside the UK, this case matters because it shows how difficult it is to set up new controlled research into puberty blockers, even after a critical government review such as the Cass Review, without immediately becoming embroiled in legal proceedings. For supporters of the trial, that is precisely the point: only robust, randomised research can provide definitive answers about the risks and benefits. Critics, however, continue to question whether children should serve as research subjects while fundamental safety questions remain unresolved. That tension—between the desire to finally gather hard data and the concern that vulnerable children could bear the ultimate burden—characterises the broader international debate over gender-affirming care for minors.